We are live on ! Find out more
SLNOW

Soleno Therapeutics, Inc. Series A Warrant
SLNOW

Delisted

SLNOW was delisted on the 8th of November, 2019.

Back to rankings

2 hedge funds and large institutions have $20K invested in Soleno Therapeutics, Inc. Series A Warrant in 2019 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2 → 2 (0)

31% less capital invested

Capital invested by funds: $29K → $20K (-$9K)

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
VC
1
Vivo Capital
California
$19K – – –
UBS Group
2
UBS Group
Switzerland
$1K – – –

SLNOW Hedge Fund Activity: Q2 2019 in Review

2 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics, Inc. Series A Warrant (SLNOW) for Q2 2019, worth a combined $20K — down 31% from $29K a quarter earlier.

Fund positioning in SLNOW was balanced in Q2 2019: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 2 institutional investors held Soleno Therapeutics, Inc. Series A Warrant (SLNOW) as of Q2 2019, unchanged from Q1 2019.
  • Funds reported $20K of Soleno Therapeutics, Inc. Series A Warrant stock for Q2 2019, down 31% quarter-over-quarter.
  • 0 funds opened new Soleno Therapeutics, Inc. Series A Warrant positions in Q2 2019 and 0 closed out.

Based on aggregated 13F filings for Q2 2019.